Beijing Mayor Visits Sinovac Biotech Ltd.

Jun 26, 2006, 01:00 ET from Sinovac Biotech Ltd.

    BEIJING, June 26 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd.
 ("Sinovac") (Amex:   SVA) announced that Wang Qishan, mayor of Beijing, and
 other government officials recently visited the Company headquarters and
 production facilities in Beijing, China.
     (Photo: http://www.newscom.com/cgi-bin/prnh/20060626/LNM005 )
     Zhu Shanlu, Secretary of Educational Working Committee of Beijing
 Municipal Party Committee, and Zhao Fengtong, vice-mayor of Beijing
 accompanied Mayor Wang on his June 17, 2006 visit. Sinovac CEO, Mr. Yin
 Weidong gave this distinguished party a status report on the Phase I
 Clinical trial preliminary results of Sinovac's proprietary pandemic
 influenza vaccine, Panflu(TM).
     Mr. Yin described the entire process of Panflu production, from virus
 cultivation, harvest, inactivation and purification, to formulation,
 filling and packaging. He also gave the visitors a tour of Sinovac's
 production facilities. During the visit, they discussed the Company's R&D
 and production process and the government's role in fostering growth in the
 biotech sector.
     Mayor Wang noted during his visit, "It is essential that we pay close
 attention to the prevention and control of infectious diseases. We must
 establish a disease prevention system for the whole society and an
 effective emergency response system to insure we are fully prepared when
 there is an outbreak of disease. To accomplish this, it is necessary for
 the government to stockpile vaccines. We must also leverage high-tech
 companies' central role in addressing national health challenges by
 supporting their technological innovations and establishing for them a
 platform of fair competition.
     About Panflu(TM)
     Sinovac's Panflu(TM) is an inactivated whole virus vaccine with
 adjuvant. Four antigen dosages levels were tested in the Phase I clinical
 trial and all of them induced an immune response in the volunteers. The
 vaccine with 10ug antigen content demonstrated the best immunogenicity,
 with a sero-positive rate of 78.3%, which exceeds the criteria for
 assessment of vaccines established by Committee for Proprietary Medicinal
 Products of the European Union.
     About Pandemic Flu
     Signs of a possible pandemic flu have emerged in Southeast Asia, as
 lethal infections in poultry and humans, and infections of the H5N1
 influenza virus strain continue to be reported. While there is no confirmed
 evidence of human-to-human transmission, there have been suspected cases
 identified in Indonesia in May 2005. It is feared that if the H5N1
 influenza virus undergoes either a genetic alteration or recombination with
 a human influenza virus, a new subtype could emerge which could be both
 highly contagious and highly lethal in humans. Such a subtype could
 potentially cause a global influenza pandemic.
     Most health officials estimate a flu pandemic could last a year or
 more, and millions of lives could be at risk. It is believed that one of
 the most effective countermeasures against pandemic flu is to manufacture
 mass quantities of vaccines as quickly as possible.
     About Sinovac
     Sinovac Biotech Ltd. is a Chinese biopharmaceutical company, focused on
 research, development and commercialization of vaccines designed to combat
 human infectious diseases. Sinovac's vaccines include Healive(TM)
 (hepatitis A), Bilive(TM) (hepatitis B) and Anflu(TM) (influenza). Sinovac
 has vaccines in clinical trials to combat avian influenza (bird flu) and
 SARS.
     Additional information about Sinovac is available on the Company
 website, http://www.sinovac.com and the Sinovac Investor Relations website,
 http://finance.groups.yahoo.com/group/Sinovac_Biotech_IR/
     To be added to our distribution list, please email: info@sinovac.com
     Safe Harbor Statement
     This announcement contains forward-looking statements. These statements
 are made under the "safe harbor" provisions of the U.S. Private Securities
 Litigation Reform Act of 1995. These forward-looking statements can be
 identified by words or phrases such as "will," "expects," "anticipates,"
 "future," "intends," "plans," "believes," "estimates" and similar
 statements. Among other things, the business outlook and quotations from
 management in this press release contain forward-looking statements.
 Statements that are not historical facts, including statements about
 Sinovac's beliefs and expectations, are forward-looking statements.
 Forward-looking statements involve inherent risks and uncertainties. A
 number of important factors could cause actual results to differ materially
 from those contained in any forward- looking statement. Sinovac does not
 undertake any obligation to update any forward-looking statement, except as
 required under applicable law.
     CONTACT:
     Craig H. Bird
     Segue Investor Relations
     Phone: (215) 885 - 4981
     Fax: (215) 885 - 4982
     Email: Sinovac@segue.biz
 
 

SOURCE Sinovac Biotech Ltd.